Please assess the completion status of the following clinical trial:

Trial Title: SUV on PSMA PET/CT in Non-Prostate Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older, able to understand and provide written informed consent~* The patient has a tumor known or suspected to have PSMA expression, as reported in the literature or by positive histopathological staining for PSMA.~* The known or suspected tumor must fall into one of the following categories: carcinoma, sarcoma, or hematologic cancer.~* ECOG performance status 0 - 3, inclusive~* Under referring physician's care~* Able to tolerate the physical/logistical requirements of a PET/CT scan including lying supine for up to 40 minutes with the arms above the head and tolerating intravenous cannulation~Exclusion Criteria:~* Patients with neoplasm known in literature to not have PSMA expression, unless patient specific tissue sampling shows PSMA staining on histopathology.~* Medically unstable patients (e.g. acute cardiac or respiratory distress or hypotensive, etc.)~* Patients who exceed the safe weight limit of the PET/CT bed (200 kg) or who cannot fit through the PET/CT bore (70 cm diameter)~* Patients with unmanageable claustrophobia~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- PSMA PET/CT (Type: EXPERIMENTAL): One (1) PSMA PET/CT scan with with either PSMA-11 or DCFPyL

Based on this trial design, predict the completion outcome and termination type (if applicable).